Hookipa Pharma Inc. (gancho): Modelo de negócios Canvas [Jan-2025 Atualizado]

A Hookipa Pharma Inc. (Hook) surge como uma empresa inovadora de biotecnologia que revoluciona o cenário da imunoterapia, empunhando tecnologias vetoriais virais de ponta que prometem soluções transformadoras para desafios médicos complexos. Ao integrar estrategicamente plataformas inovadoras de pesquisa, parcerias colaborativas e experiência científica avançada, a Hookipa está posicionada na vanguarda do desenvolvimento de abordagens terapêuticas personalizadas direcionadas a necessidades médicas críticas não atendidas em oncologia e tratamento de doenças infecciosas. Seu modelo de negócios exclusivo representa uma mistura sofisticada de inovação científica, parcerias estratégicas e potencial inovador que poderia redefinir intervenções imunológicas na área da saúde moderna.

Hookipa Pharma Inc. (gancho) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa farmacêutica e centros acadêmicos

Hookipa Pharma estabeleceu parcerias com as seguintes instituições de pesquisa:

Instituição	Foco de colaboração
Escola de Medicina da Universidade de Washington	Pesquisa de imunoterapia
Universidade da Califórnia, São Francisco	Desenvolvimento de tecnologia vetorial viral

Colaborações estratégicas com empresas farmacêuticas

As principais parcerias estratégicas incluem:

• Boehringer Ingelheim - Colaboração de Pesquisa Oncológica
• Genentech - Desenvolvimento da plataforma de imunoterapia

Organizações de pesquisa contratada (CROs)

Hookipa trabalha com CROs especializados para gerenciamento de ensaios clínicos:

Cro	Fase de ensaios clínicos	Ensaios ativos
Iqvia	Fase I/II	3 ensaios em andamento
Parexel	Fase II/III	2 ensaios em andamento

Parceiros de imunoterapia e desenvolvimento de vacinas

Redes colaborativas para pesquisa avançada de imunoterapia:

• Institutos Nacionais de Saúde (NIH) - Desenvolvimento de Vacinas
• Instituto de Câncer Dana -Farber - Imunoterapia Oncológica

Redes de pesquisa de biotecnologia

Hookipa participa das seguintes redes de pesquisa de biotecnologia:

• Rede de Instituto de Pesquisa do Câncer
• Consórcio do Centro de Pesquisa de Vacinas

Total de Pesquisa Parcerias em 2024: 12 colaborações ativas

Hookipa Pharma Inc. (gancho) - Modelo de negócios: Atividades -chave

Desenvolvendo novas plataformas imunoterapêuticas

A Hookipa Pharma se concentra no desenvolvimento de plataformas imunoterapêuticas de vetores virais proprietários. Em 2023, a empresa investiu US $ 18,3 milhões em pesquisa e desenvolvimento para essas plataformas.

Tecnologia da plataforma	Investimento (2023)	Estágio atual
vetores baseados em arenavírus	US $ 7,2 milhões	Desenvolvimento pré -clínico
Vetores de imunoterapia de células T	US $ 6,5 milhões	Ensaios clínicos
Novos projetos de vetores virais	US $ 4,6 milhões	Fase de pesquisa

Condução de pesquisa pré -clínica e clínica

Hookipa Pharma conduz ativamente pesquisas em várias áreas terapêuticas.

• Número de estudos pré -clínicos em andamento: 5
• Número de ensaios clínicos ativos: 3
• Pessoal de pesquisa total: 62 cientistas
• Instalações de pesquisa: 2 centros de pesquisa dedicados

Projetando tecnologias de vacinas baseadas em vetores virais

A Companhia desenvolveu múltiplas tecnologias de vacinas vetoriais virais direcionadas a indicações específicas de doenças.

Tecnologia da vacina	Indicação alvo	Estágio de desenvolvimento
HB-101	Tumores sólidos	Fase 1/2 ensaios clínicos
HB-201	Cânceres relacionados ao HPV	Desenvolvimento pré -clínico
HB-202	Câncer de próstata	Estágio de investigação

Avançar imunoterapias de células T

A Hookipa Pharma investiu US $ 12,7 milhões em pesquisa de imunoterapia com células T em 2023.

• Programas de terapia de células T: 4 programas distintos
• Patentes de propriedade intelectual: 17 relacionadas às tecnologias de células T
• Parcerias de pesquisa colaborativa: 3 instituições acadêmicas

Buscando aprovações regulatórias para candidatos terapêuticos

A empresa se envolve ativamente com órgãos regulatórios para possíveis aprovações terapêuticas.

Candidato terapêutico	Status regulatório	Linha do tempo de aprovação potencial
HB-101	Designação de pista rápida da FDA	2025-2026
HB-201	IND Pedido enviado	2024-2025

Hookipa Pharma Inc. (gancho) - Modelo de negócios: Recursos -chave

Plataformas de tecnologia de vetores virais proprietários

A plataforma de tecnologia principal da Hookipa Pharma inclui:

• Plataforma de tecnologia vetor viral Targetvec
• Novos projetos de vetores virais não replicantes

Plataforma de tecnologia	Características únicas	Estágio de desenvolvimento
Targetvec	Sistema de vetor viral não replicante	Validado clinicamente

Portfólio de propriedade intelectual

Em 31 de dezembro de 2023, a Hookipa Pharma detida:

• 22 patentes emitidas em todo o mundo
• Múltiplos pedidos de patente pendente

Equipe de pesquisa e desenvolvimento

Categoria de pessoal	Número de funcionários
Funcionários totais de P&D	38
Pesquisadores de nível de doutorado	24

Instalações avançadas de laboratório e pesquisa

Localizado em Nova York, NY, com infraestrutura de pesquisa especializada para o desenvolvimento de imunoterapia.

Experiência científica

• Focado na imunoterapia de células T
• Experiência em engenharia vetorial viral
• Especializado em oncologia e pesquisa de doenças infecciosas

Orçamento de pesquisa para 2024: US $ 24,3 milhões

Hookipa Pharma Inc. (Hook) - Modelo de Negócios: Proposições de Valor

Soluções inovadoras de imunoterapia para doenças desafiadoras

A Hookipa Pharma desenvolve imunoterapias baseadas em vetores virais direcionados a áreas específicas de doenças. No quarto trimestre 2023, a empresa se concentrou no desenvolvimento de novas abordagens terapêuticas com as seguintes características importantes:

Plataforma de tecnologia	Foco terapêutico	Estágio de desenvolvimento
Vetor viral rnai	Imunoterapia contra o câncer	Fase 1/2 ensaios clínicos
TECNOLOGIA TRIMIX	Doenças infecciosas	Desenvolvimento pré -clínico

Possíveis tratamentos inovadores para câncer e doenças infecciosas

O oleoduto de Hookipa inclui vários tratamentos potenciais inovadores:

• HB-200 para câncer relacionado ao HPV
• HB-201 para tumores sólidos
• HB-202 para câncer de próstata

Tecnologia vetor viral exclusiva

A tecnologia de vetores virais proprietários da empresa demonstra as principais vantagens:

Atributo de tecnologia	Capacidade específica
Eficiência vetorial	Altas taxas de transdução celular
Ativação imune	Mecanismos aprimorados de resposta de células T

Abordagens imunológicas personalizadas

A pesquisa de Hookipa se concentra em estratégias de imunoterapia personalizadas com mecanismos de segmentação específicos:

• Identificação de antígeno específica do paciente
• Modulação do sistema imunológico de precisão
• Otimização de resposta imune adaptativa

Tecnologias avançadas de plataforma

Métricas financeiras e de pesquisa para as tecnologias de plataforma da Hookipa:

Métrica	2023 valor
Despesas de P&D	US $ 47,2 milhões
Portfólio de patentes	23 patentes concedidas
Investimentos de ensaios clínicos	US $ 18,6 milhões

Hookipa Pharma Inc. (Hook) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento com instituições de pesquisa

A partir do quarto trimestre 2023, a Hookipa Pharma manteve colaborações de pesquisa ativa com 12 instituições acadêmicas e de pesquisa. O financiamento total de pesquisa colaborativa em 2023 foi de US $ 3,2 milhões.

Tipo de instituição de pesquisa	Número de colaborações ativas	Alocação de financiamento
Universidades acadêmicas	8	US $ 2,1 milhões
Centros de pesquisa	4	US $ 1,1 milhão

Comunicação direta com parceiros farmacêuticos

Em 2023, a Hookipa Pharma estabeleceu parcerias com 5 empresas farmacêuticas para potencial desenvolvimento de imunoterapia.

• Os valores do contrato de parceria variaram de US $ 500.000 a US $ 3,5 milhões
• Duração média da parceria: 24-36 meses
• Principais áreas de foco: imunoterapias virais e tratamentos contra o câncer

Conferência Científica e Participação de Eventos da Indústria

Hookipa Pharma participou de 17 conferências científicas internacionais em 2023, com despesas totais relacionadas a eventos de US $ 425.000.

Tipo de conferência	Número de conferências	Sessões de apresentação
Conferências de oncologia	7	12
Simpósios de imunoterapia	6	9
Conferências de Virologia	4	6

Atualizações transparentes de pesquisa e desenvolvimento

A Hookipa Pharma lançou 24 atualizações de pesquisa pública em 2023, com a comunicação digital atingindo aproximadamente 45.000 contatos profissionais.

• Canais de comunicação digital: LinkedIn, revistas científicas, site corporativo
• Taxa de engajamento médio: 3,2% nas plataformas
• Orçamento total da comunicação: US $ 275.000

Abordagem de pesquisa colaborativa

A Hookipa Pharma investiu US $ 7,8 milhões em iniciativas de pesquisa colaborativa durante 2023, representando 22% do total de despesas de P&D.

Área de pesquisa colaborativa	Investimento	Parceiros de pesquisa
Imunoterapia contra o câncer	US $ 3,5 milhões	6 parceiros
Tecnologias vetoriais virais	US $ 2,7 milhões	4 parceiros
Pesquisa de terapia genética	US $ 1,6 milhão	3 parceiros

Hookipa Pharma Inc. (Hook) - Modelo de Negócios: Canais

Publicações e apresentações científicas

Hookipa Pharma utiliza publicações e apresentações científicas como um canal crítico para comunicar os resultados da pesquisa e o progresso clínico.

Tipo de publicação	Frequência (2023)	Plataformas principais
Artigos de periódicos revisados ​​por pares	4-6 publicações	Biotecnologia da natureza, Journal of Immunology
Apresentações da conferência	8-10 apresentações científicas	AACR, ASCO, Ash

Comunicações de Relações com Investidores

Hookipa mantém canais robustos de comunicação para investidores.

• Chamadas de ganhos trimestrais
• Reuniões anuais de acionistas
• Apresentações de investidores
• Registros da SEC

Canal de comunicação	Freqüência	Alcance do investidor
Webcast de ganhos	Trimestral	Aproximadamente 150-200 investidores institucionais
Conferências de investidores	4-6 anualmente	Mais de 500 investidores em potencial

Diretor de desenvolvimento de negócios direto

Hookipa se envolve em estratégias direcionadas de desenvolvimento de negócios.

• Negociações de parceria farmacêutica
• Discussões de licenciamento
• Reuniões estratégicas de colaboração

Conferências da indústria farmacêutica

Os principais eventos da indústria servem como plataformas críticas de rede e comunicação.

Conferência	Tipo de participação	2023 Engajamento
Reunião Anual da ASCO	Apresentação de pôsteres	2 resumos de pesquisa
Conferência de Saúde JP Morgan	Apresentação da empresa	1 Apresentação corporativa

Plataformas científicas e de investidores online

Os canais digitais complementam os métodos tradicionais de comunicação.

• Site da empresa
• Página corporativa do LinkedIn
• Portal de Relações com Investidores
• Perfis de banco de dados científicos

Plataforma digital	Engajamento mensal (estimado)	Propósito primário
Site corporativo	5.000-7.000 visitantes únicos	Disseminação da informação
LinkedIn	2.500-3.500 impressões	Networking profissional

Hookipa Pharma Inc. (gancho) - Modelo de negócios: segmentos de clientes

Instituições de pesquisa farmacêutica

A Hookipa Pharma tem como alvo instituições de pesquisa farmacêutica com foco específico em plataformas de imunoterapia. A partir do quarto trimestre 2023, a base de clientes da empresa neste segmento inclui:

Tipo de instituição	Número de clientes em potencial	Foco na pesquisa
Centros de Pesquisa Nacional	37	Imunoterapias vetoriais virais
Laboratórios de Pesquisa Privada	64	Imunoterapia contra o câncer

Empresas de biotecnologia

O segmento de clientes da Hookipa para empresas de biotecnologia inclui:

• Empresas de biotecnologia focadas em oncologia: 42 empresas
• Empresas de doenças infecciosas Empresas de biotecnologia: 28 empresas
• Potencial de receita de mercado total endereçável: US $ 124,5 milhões

Centros Médicos Acadêmicos

Engajamento do cliente com centros médicos acadêmicos:

Tipo central	Número de parcerias	Áreas de pesquisa
Centros de pesquisa do câncer	19	Desenvolvimento de imunoterapia
Centros de doenças infecciosas	12	Tecnologias vetoriais virais

Provedores de tratamento de oncologia

Principais segmentos de clientes no tratamento de oncologia:

• Centros abrangentes de câncer: 23
• Clínicas Oncológicas Especializadas: 56
• Alcance potencial total do mercado: 79 provedores de tratamento

Pesquisadores de doenças infecciosas

Base de clientes da Hookipa em pesquisa de doenças infecciosas:

Categoria de pesquisa	Número de clientes em potencial	Foco na pesquisa
Instituições de Pesquisa Governamental	15	Desenvolvimento de vacina vetorial viral
Laboratórios de pesquisa independentes	22	Imunologia e doenças infecciosas

Hookipa Pharma Inc. (gancho) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

De acordo com o relatório anual de Hookipa Pharma 2022, as despesas totais de P&D foram de US $ 41,5 milhões no ano fiscal.

Ano	Despesas de P&D	Porcentagem do total de despesas operacionais
2022	US $ 41,5 milhões	68.3%
2021	US $ 36,2 milhões	65.7%

Investimentos de ensaios clínicos

As despesas de ensaios clínicos da Hookipa Pharma em 2022 totalizaram US $ 22,3 milhões, representando uma parcela significativa das despesas de P&D.

• Ensaios de Fase I: US $ 8,7 milhões
• Ensaios de Fase II: US $ 13,6 milhões

Manutenção de propriedades patentes e intelectuais

Os custos anuais de manutenção da propriedade intelectual foram de US $ 1,2 milhão em 2022, cobrindo as despesas de arquivamento, acusação e renovação de patentes.

Pessoal e recrutamento de talentos científicos

Categoria de pessoal	Número de funcionários	Custo anual do pessoal
Cientistas de pesquisa	45	US $ 6,8 milhões
Pesquisadores clínicos	32	US $ 4,9 milhões
Equipe administrativo	28	US $ 2,3 milhões

Infraestrutura e equipamento de tecnologia

Os investimentos em tecnologia e equipamentos em 2022 totalizaram US $ 5,6 milhões.

• Equipamento de laboratório: US $ 3,2 milhões
• Infraestrutura de TI: US $ 1,4 milhão
• Software e ferramentas digitais: US $ 1,0 milhão

Hookipa Pharma Inc. (gancho) - Modelo de negócios: fluxos de receita

Acordos de licenciamento em potencial

A partir do quarto trimestre 2023, a Hookipa Pharma relatou potencial potencial de receita de licenciamento para sua plataforma de imunoterapia viral. Não foram divulgados valores específicos de negócios de licenciamento em suas demonstrações financeiras.

Colaborações de pesquisa

Parceiro de colaboração	Receita potencial	Foco na pesquisa
Gilead Sciences	Pagamento inicial de US $ 26 milhões	Imunoterapia viral HB-101

Vendas futuras de produtos terapêuticos

O oleoduto de Hookipa se concentra no desenvolvimento de imunoterapias virais com possíveis vendas futuras em:

• Imunoterapias contra o câncer
• Tratamentos de doenças infecciosas

Concessão de financiamento

Em 2023, a Hookipa recebeu subsídios de pesquisa, totalizando aproximadamente US $ 2,5 milhões de várias instituições de pesquisa científica.

Pagamentos marcantes de parcerias estratégicas

Parceria	Potenciais pagamentos marcantes	Valor potencial total
Gilead Sciences Collaboration	Até US $ 1,2 bilhão	US $ 1,2 bilhão

A receita total da Hookipa Pharma em 2023 foi de US $ 30,4 milhões, principalmente de receitas de colaboração e subsídios de pesquisa.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Value Propositions

You're looking at the core reasons why HOOKIPA Pharma Inc. (HOOK) built its platform; these are the unique things they offer.

Inducing uniquely potent, antigen-specific CD8+ T-cell responses against cancer is central. The arenavirus platform is engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies.

The platform versatility spans therapeutic oncology and prophylactic infectious diseases. The company operates two complementary platform technologies: an engineered Modified Vaccinia Ankara (MVA) vector and an arenavirus vector system.

For chronic infectious diseases, the potential for functional cures is tied to the Gilead-owned assets. The HB-500 program alone had a potential future value of $232.5 million in opt-in, development, and commercial milestone payments, plus royalties. The HB-500 Phase 1b trial enrolled 30 participants across five U.S. sites, with primary completion expected in H2 2025.

Durable immunity with a favorable safety profile shows up clearly in the oncology data. Here's the quick math on the HB-200 + pembrolizumab data:

Metric	Value	Context
Patients Enrolled (Phase 2)	68	HPV16+ HNSCC study (H200-001)
Objective Response Rate (ORR)	52%	Late-breaking SITC 2024 data (CPS ≥20 patients)
Disease Control Rate (DCR)	80%	Late-breaking SITC 2024 data (CPS ≥20 patients)
12-Month Overall Survival (OS)	83%	Late-breaking SITC 2024 data (CPS ≥20 patients)
Grade ≥3 TRAEs	14%	Phase 1/2 combination therapy
Serious TRAEs	7%	Phase 1/2 combination therapy

The company's strategic pivot in 2025 focused resources, evidenced by the Trailing Twelve Month (TTM) revenue as of late 2025 being $9.35 million USD. The stock price as of 07-Nov-2025 was $0.89, with a market cap of $11M.

The platform's capabilities are further detailed by:

• Platform uses arenavirus and Modified Vaccinia Ankara (MVA) vectors.
• HB-500 trial enrolled 30 participants.
• Q3 2025 revenue was reported at $4.70M.
• EPS for 12 months was -$5.84.
• The sale of HB-500 and HB-400 assets closed on October 30, 2025.

Finance: review the final closing statement from the Gilead asset sale by next Tuesday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Customer Relationships

You're looking at the relationships HOOKIPA Pharma Inc. maintains with its key external groups as of late 2025, following a significant strategic realignment. This is all about managing the remaining collaborations, keeping the remaining investors informed, and continuing to build scientific credibility.

High-touch, strategic collaboration management with Big Pharma partners

The relationship with Big Pharma partners, particularly Gilead Sciences, Inc., has been the core of the revenue generation model. This relationship underwent a major shift in late 2025. The collaboration, which began with an agreement dated February 15, 2022, saw a significant transaction on October 31, 2025, with the completion of the sale of assets related to the HB-400 program and certain HB-500 assets to Gilead. This suggests a high-touch management structure was in place to execute such a complex divestiture while managing the ongoing Phase 1b clinical trial of HB-500, which was being developed in collaboration with Gilead.

Revenue generation is directly tied to these relationships. For instance, HOOKIPA Pharma Inc. generated $2 million in total revenue in Q1 2025, which reflected the entirety of their revenue coming from collaborations and licensing agreements. While specific milestone payments received in the latter half of 2025 are not detailed, a $5.0 million milestone payment was received in July 2024 related to the HB-500 program. The nature of these relationships requires dedicated management to ensure milestone achievement and potential future commercialization success, even after the asset sale.

Here's a look at the key partnership activities and financial tie-ins:

Key Partner Event/Program	Date/Period	Associated Financial/Statistical Data
Sale of HB-400/HB-500 Assets to Gilead Completion	October 31, 2025	Transaction completed following Q3 2025 reporting
HB-500 Phase 1b Trial Dosing (Gilead Collaboration)	Initiated July 1, 2024	Resulted in a $5.0 million milestone payment in July 2024
Q1 2025 Collaboration/Licensing Revenue	Q1 2025	$2 million total revenue
Original Collaboration Agreement Date (with Gilead)	February 15, 2022	Governing document for the divested assets

Investor relations focused on communicating the strategic pivot and financial runway

Investor relations in late 2025 centered on communicating the strategic pivot, which included the asset sale to Gilead and a major corporate action: the announcement of the intention to voluntarily delist and deregister its common stock on July 18, 2025. This communication strategy is critical for a clinical-stage company still in development. You need to clearly articulate the path forward after shedding key assets.

The financial context for this communication is important. The company reported a net loss of $-15.43 million in Q1 2025. As of May 12, 2025, the outstanding share count was 9,789,622 shares of common stock and 2,399,517 shares of Class A common stock. Communicating the financial runway post-asset sale, even if future funding is not deemed probable in SEC filings as of May 2025, becomes the primary focus for investors holding shares after the delisting announcement.

Key investor relations touchpoints and data points include:

• Intention to voluntarily delist announced on July 18, 2025.
• Q1 2025 net loss reported at $-15.43 million.
• Total common and Class A shares outstanding as of May 12, 2025: 12,189,139 shares (sum of 9,789,622 and 2,399,517).
• The company's primary communication channels include the investor relations website, SEC filings, press releases, and public conference calls.

Scientific engagement through publications and conferences

Maintaining scientific credibility is non-negotiable for a platform-based biopharma company, even after significant restructuring. Engagement continues through presenting data at key medical meetings and publishing peer-reviewed work. While the most recent publications cited are from 2021, the company actively presented data throughout 2024, which sets the stage for late 2025 engagement strategy.

Recent scientific engagement highlights include:

• Poster presentation on Eseba-vec (HB-200) in combination with pembrolizumab at SITC 2024.
• Presentation of HB-200 ASCO 2024 data update.
• Presentation of preclinical proof-of-concept data for HB-700 at the 6th Annual RAS-Targeted Drug Development Summit on September 25, 2024.

The core technology remains the proprietary arenavirus platform, which is designed to reprogram the body's immune system for cancer and infectious diseases. The focus post-sale appears to be on the remaining pipeline, such as HB-700, which is a Phase 1-ready immunotherapy for KRAS-mutated cancers.

Scientific Communication Venues (Based on 2024 Activity):

Forum Type	Specific Event/Topic	Relevance to Platform/Pipeline
Major Oncology Conference	SITC 2024	HB-200 (eseba-vec) + pembrolizumab data
Major Oncology Conference	ASCO 2024	HB-200 data update
Targeted Summit	RAS-Targeted Drug Development Summit 2024	HB-700 preclinical data
Peer-Reviewed Literature	Publications	Platform validation (e.g., Nature Communications, Cell Reports Medicine from 2021)

Finance: review the projected cash burn rate against the remaining assets and projected milestone receipts for the next four quarters by Monday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Channels

You're looking at the channels for HOOKIPA Pharma Inc. as of late 2025, and honestly, the picture is dominated by a strategic wind-down following a major asset transaction. The company's primary channels shifted from broad partnership development to the execution of an asset sale and subsequent dissolution process.

Direct licensing and collaboration agreements with major biopharma companies

The most significant channel activity involved the conclusion of key collaborations through a definitive Asset Purchase Agreement. On May 21, 2025, HOOKIPA Pharma entered this agreement with Gilead Sciences, Inc.. This agreement involved the sale of assets primarily related to the HB-400 (HBV) and HB-500 (HIV) programs. The total consideration for this channel exit was structured for up to $10 million. This contrasts with the prior potential value tied to these programs under the original collaboration structure, which included milestones up to $140 million for the HBV program and up to $172.5 million for the HIV program, plus royalties. Following stockholder approval on July 29, 2025, the company initiated steps to voluntarily delist from Nasdaq and proceed with dissolution.

The channel for communicating these material financial events relies heavily on official disclosures:

• Investor relations website: https://ir.hookipapharma.com
• SEC filings, including Form 8-K on July 18, 2025, announcing delisting intent
• Press releases and public conference calls

Here's the quick math on the key partnership channel that just concluded:

Program/Asset	Partner	Channel Status (Late 2025)	Potential Milestone Value (Pre-Sale)	Final Transaction Value
HB-400 (HBV) & HB-500 (HIV) Assets	Gilead Sciences, Inc.	Transferred via Asset Purchase Agreement	Up to $140 million (HBV) + $172.5 million (HIV)	Up to $10 million total
HB-700 (KRAS Vaccine)	Internal/Independent	Advancing into Phase 1 trials	N/A	N/A
Eseba-vec (HB-200)	N/A	Development paused	N/A	N/A

Clinical trial sites and networks for product candidate testing

The clinical trial network channel is in a state of transition due to the strategic shift. For the assets sold to Gilead, the Phase 1b trial for the HIV therapeutic vaccine (HB-500) completed enrollment as of January 30, 2025. This means the site network activity for that program has effectively transferred or concluded under HOOKIPA Pharma Inc.'s direct management. For the retained HB-700 program, the company affirmed commitment to advancing it into Phase 1 trials independently. The operational focus for site management would be on ensuring smooth handover or winding down of the transferred trials while setting up the necessary infrastructure for the independent HB-700 Phase 1 initiation, though specific site counts aren't public.

The company's TTM revenue as of March 31, 2025, was $9.35 Million USD, which reflects the operational scale before the asset sale closed, likely covering ongoing trial support and R&D expenses.

Scientific and medical conferences for data presentation

This channel serves to validate the science and attract partners, but in late 2025, its role is more about presenting the remaining pipeline data and fulfilling prior commitments. The most recent public data presentations noted were from 2024 events, such as the ASCO Data Update on June 4, 2024. As of the search results, there were currently no upcoming events scheduled for HOOKIPA Pharma Inc.. The company's communication strategy, especially post-delisting intent, prioritizes SEC filings and the investor relations website over active conference participation for broad outreach.

The company's market valuation reflects this channel shift and corporate status as of November 7, 2025:

• Stock Price: $0.89
• Market Cap: $11M
• Shares Outstanding: 12.3M

Finance: draft 13-week cash view by Friday.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Customer Segments

You're looking at the customer segments for HOOKIPA Pharma Inc. as the company finalized a major strategic shift in late 2025. This isn't a typical ongoing business profile; it reflects the entities involved in the wind-down and asset transfer process.

The core customer segments, or counterparties, HOOKIPA Pharma Inc. engaged with included:

• - Global pharmaceutical and biotechnology companies (B2B partners).
• - Patients with HPV16+ head and neck cancers (primary clinical focus).
• - Patients with chronic infectious diseases (e.g., HIV, HBV) via partners.
• - Institutional and retail investors.

The B2B partner segment saw a definitive transaction with Gilead Sciences, Inc., which acquired assets related to the HB-400 (HBV) and HB-500 (HIV) programs, closing on October 30, 2025. The total consideration for this Asset Purchase Agreement was up to $10,000,000 in cash.

The financial breakdown of the Gilead transaction involved:

Payment Component	Amount
Cash Due at Closing (May 21, 2025 transaction)	$3,000,000
Maximum Contingent Payment (Milestones)	Up to $7,000,000

For the patient segment focused on oncology, the lead candidate was eseba-vec for Human Papillomavirus type 16 positive (HPV16+) cancers.

Patient engagement numbers related to the HPV16+ Head and Neck Squamous Cell Carcinoma (HNSCC) program included:

• - Enrollment completed in the Phase 2 H200-001 study (eseba-vec + pembrolizumab) with 68 patients enrolled as of October 2024.
• - An Investigator-Initiated Trial (IIT) for adjuvant therapy in HPV16+ HNSCC was expected to enroll approximately 50 patients.

The infectious disease patient segment, specifically for HIV (HB-500) and Hepatitis B Virus (HBV) (HB-400), was largely transferred to Gilead. The Phase 1b clinical trial evaluating HB-500 for HIV treatment had completed enrollment as of May 2025.

The investor segment, both institutional and retail, was actively tracking the company through its transition period, including the announced delisting from Nasdaq.

Key investor metrics as of mid-to-late 2025:

• - Stock price as of November 07, 2025: $0.89.
• - Market Capitalization as of November 07, 2025: $11M.
• - Shares outstanding as of November 07, 2025: 12.3M.
• - Institutional owners filing 13D/G or 13F forms (as of August 7, 2025): 23.
• - Total shares held by these institutions (as of August 7, 2025): 510,921 shares.
• - Trailing Twelve Month (TTM) Revenue as of March 31, 2025: $9.4M.

The aggregate market value of Common Stock held by non-affiliates on June 30, 2024, was approximately $57.0 million.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Cost Structure

You're looking at the cost structure for HOOKIPA Pharma Inc. as the company executes its wind-down following the asset sale and voluntary delisting. The cost base is heavily weighted toward the science, even in this final phase.

The primary cost driver remains the high research and development (R&D) expenses necessary to support ongoing clinical programs, even as the company streamlines operations. For the year ended February 28, 2025, HOOKIPA Pharma Inc. reported Research and development expenses of $68.5 million. This figure represented a decrease of $17.9 million compared to 2023, directly attributed to the Restructuring Plan and reduced direct and indirect research and development spending. Overall, Total operating expenses for that period were $95.4 million, down $22.4 million from the prior year.

Personnel costs are a major component, even after significant workforce adjustments. While the specific financial impact of the 80% reduction plan approved in late 2024 isn't isolated in the latest filings, the restructuring itself was a key factor in reducing the overall operating expense base. To give you a concrete example of executive compensation, the employment agreement for Chief Executive Officer and President Malte Peters sets his annual base salary at $630,000.

General and administrative (G&A) expenses also factor in, covering necessary overhead like legal and intellectual property (IP) maintenance to manage the wind-down. General and administrative expenses for the year ending February 28, 2025, totaled $20.2 million. Honestly, that was an increase of $1.6 million over 2023, driven mainly by higher professional and consulting fees, likely associated with the strategic evaluation and subsequent dissolution process.

Costs associated with the voluntary delisting from Nasdaq in 2025 are a direct consequence of the decision to cease public reporting obligations to reduce economic burdens on the remaining assets. HOOKIPA notified Nasdaq of its intent to voluntarily delist on July 18, 2025, with the deregistration process expected to be effective around August 8, 2025. The company explicitly noted that continuing to comply with applicable reporting requirements would be economically burdensome and reduce assets available for ultimate distribution to stockholders.

Here's a quick look at the key expense components from the latest reported full fiscal year data, which frames the cost base leading into the late 2025 liquidation phase:

Cost Component	Amount (Millions of US $)	Comparison Context
Research and Development Expenses	$68.5	Decrease of $17.9 million from 2023 due to Restructuring Plan
General and Administrative Expenses	$20.2	Increase of $1.6 million from 2023 due to professional fees
Total Operating Expenses	$95.4	Decrease of $22.4 million from the previous year
Loss from Operations	$51.5	Significant improvement from $97.7 million in 2023

The overall cost structure reflects a company aggressively cutting burn rate to maximize shareholder returns during dissolution. The major expenditures are now focused on winding down clinical obligations and legal/administrative requirements for the final corporate actions.

• High R&D spend is concentrated on advancing the eseba-vec and HB-700 programs.
• Personnel costs are being managed via the Restructuring Plan implemented earlier in the year.
• G&A includes fees related to the asset sale and dissolution proceedings.
• The delisting decision was made to eliminate ongoing, economically burdensome SEC reporting costs.

Finance: draft 13-week cash view by Friday, incorporating final severance accruals.

HOOKIPA Pharma Inc. (HOOK) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of HOOKIPA Pharma Inc. (HOOK) as of late 2025, and honestly, the picture is dominated by the recent strategic shift-specifically, the sale of its core infectious disease assets. This means the current revenue profile is heavily weighted toward the tail end of prior agreements and milestone recognition, rather than ongoing product sales, which the company itself noted it doesn't have.

As of late 2025, the Trailing Twelve Months (TTM) revenue for HOOKIPA Pharma Inc. (HOOK) is approximately $9.35 million USD. This figure reflects the recognition of deferred revenue and final payments following major partnership restructuring.

Collaboration and Licensing Income

The primary source of reported income has been from collaboration and licensing activities, which is typical for a clinical-stage biotech. For the three months ending September 30, 2024, the collaboration and licensing revenue was reported at $4.7 million. This was a decrease from the $6.9 million reported in the same period of 2023, partly due to the termination of the Roche collaboration agreement.

To give you a sense of the historical context that shaped the current TTM number, consider the revenue trend:

Period	Reported Revenue
2023 Annual Revenue	$20.12 Million USD
2024 Annual Revenue	$43.94 Million USD
Q1 2025 Revenue	$2 million

The Q1 2025 revenue of $2 million compared quite starkly to the $36.60 million seen in Q1 2024. This sharp drop underscores the transition away from active, multi-asset collaborations.

Upfront and Milestone Payments from Strategic Partners

The most significant financial events revolve around the strategic partners, particularly Gilead Sciences, Inc. The recent asset sale to Gilead, which included the HBV (HB-400) and HIV (HB-500) programs, was a major component of the company's financial structure leading up to its decision to liquidate. This transaction involved specific, concrete payments that feed into the revenue recognition schedule.

Here are the key components related to the Gilead partnership that impact revenue streams:

• - The asset sale to Gilead included an immediate upfront payment of $3 million for the sale of the HBV/HIV programs.
• - The total potential payout from Gilead for these assets was structured to reach up to $422.5 million in milestones and royalties.
• - In July 2024, HOOKIPA Pharma Inc. received a success-based milestone payment of $5.0 million from Gilead related to the dosing of the first subject in the Phase 1b clinical trial of HB-500 for HIV-1.
• - The original 2018 collaboration agreement with Gilead provided an upfront payment of $10 million.
• - An amended 2022 agreement included a $15 million initiation fee and a $5 million equity investment from Gilead.

The sale of these vaccine rights to Gilead constituted substantially all of HOOKIPA Pharma Inc.'s assets, leading to the subsequent plan to wind down operations, as the company stated it has 'no product candidates that generate revenue.' This means the $9.35 million TTM revenue is largely the final recognition of these prior deals, not new, ongoing operational revenue.